93. The United States thanks the Secretariat for the informative report. The previous interventions of the US on the agenda item concerning IP Measures in the Context of COVID19 stand. As previously stated, intellectual property plays an incentivizing role in the development of new technologies to combat this deadly pandemic and in supporting economic recovery. In past meetings, the US highlighted the U.S. Patent and Trademark Office COVID19 pilot programme which prioritizes examination of certain patent applications claiming a product or process subject to an applicable FDA approval for COVID19 use, and a companion FastTrack Pilot Program for Appeals Related to COVID19. 94. As of 1 March 2022, 906 applications have been granted prioritized examination status in the USPTO's COVID-19 Prioritized Examination Pilot Program, and 591 patents have issued from applications granted priority status under this pilot programme. The pilot programme was originally set to expire after the USPTO accepted 500 applications into the programme, but this application limit has been removed. The pilot will include all qualifying patent applications received by midnight Eastern Time on 31 March 2022. Further information on the USPTO's initiatives on life science technologies can be found on the COVID-19 Response Resource Center page of USPTO.gov. 95. Also, as mentioned previously, in 2021 the USPTO launched a category of its Patents for Humanity Program for inventions that address the COVID-19 pandemic. This new category will provide business incentives for patent applicants, holders, and licensees whose inventions track, prevent, diagnose, or treat COVID-19. The application period for the new category ended on 30 September 2021 and the USPTO is currently in the judging phase of this programme. We will announce winners for this programme by fall 2022.
© World Trade Organization 2023
ver 188.8.131.5229 (26/08/2022 10:49 AM)